SmCC commonly harbors combined alterations in both TP53 and RB1 [71,89]; however, whether this genomic instability actually favors lineage switching from oncogene-addicted urothelial cells to NE-like tumor cells, along with a decreased response to targeted therapy, is still debated. Here, TP53 is linked to neoplasm.